OIS-Europe-MAIN-Final

PRODUCED IN COLLABORATION WITH

An OIS showcase featuring European ophthalmic start-ups was long overdue.
Not only will you see presentations from 8 innovative companies but a keynote discussion with Tim Clover,
CEO of Rayner and a panel discussion with some of the top European industry executives.

OIS Register - European Social

PROUDLY SPONSORED BY:

Allergan

Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world.  The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.

Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.  Headquartered in Leuven, Belgium, Oxurion is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company.

MEDIA PARTNER:

AGENDA | SEPTEMBER 23

12:00 – 12:05 PM

Welcome and Introduction to OIS

Presented By:
Bill Link, PhD, Managing Partner - Flying L Partners

12:05 – 12:15 PM

European Ophthalmology Market Overview: Legacy of Innovation in Europe Past to Present Day

Presented By:
Joe Sullivan, CEO - Emmetropes

12:15 – 12:45 PM

Rayner: A European Innovation Success Story

Participant:
Tim Clover, CEO - Rayner

Interviewed By:
Joe Sullivan, CEO - Emmetropes

12:45 – 1:30 PM

European Company Showcase

Introduced By:
Mark Mayhew, Partner - Emmetropes

Oxurion | Patrik De Haes, MD, CEO
Voptica | Pablo Artal, PhD, Co-founder & CEO
Oculis | Marcia de Souza Lima, MD, Chief Medical Officer
Implandata Ophthalmic Products GmbH | Max G. Ostermeier, MBA, Founder & CEO
Resono Ophthalmic | Alfredo Ruggeri, President & CEO
KERANOVA | Michael Brownell, Strategic Advisor

1:30 – 2:30 PM

The Future of Ophthalmic Innovation in Europe - Drivers & Challenges

Participants:
Laurent Attias, SVP, Corporate Development Strategy, BD&L and M&A - Alcon
Jean-Frédéric Chibret, President - Théa
Fabrizio Chines, CEO - SIFI
Andrea Ponti, Managing Partner & Founder - GHO Capital
Dietrich Wolf, CEO – Eye Tech Care

Moderated By:
Javier Mendicute, MD, PhD

2:30 – 3:15 PM

Virtual Networking

GET INVOLVED

Learn how your company can get involved in another successful OIS meeting.

SPONSOR THIS EVENT

Gain valuable exposure and visibility for your company's branding.

APPLY TO PRESENT

Increase awareness of your technology & the
developmental stage of your company.

SUBSCRIBE TO OUR NEWSLETTER

Weekly Newsletters About The Latest In Ophthalmic Innovation.

JOIN US ON LINKEDIN

Connect and converse with nearly 5,000
innovative ophthalmic professionals.